Background
Although the prognosis of patients with colorectal cancer (CRC) is steadily improving, the disease remains the second most common cause of cancer-related deaths in Europe [
1]. The treatment of CRC is dependent on the disease stage and the location of the tumor. Conventional treatment includes surgery, radiation and chemotherapy (5-fluorouracil, irinotecan and/or oxaliplatin) [
2], often combined with bevacizumab (a neutralizing antibody against vascular endothelial growth factor; VEGF) or cetuximab/panitumumab (neutralizing antibodies against epidermal growth factor receptor; EGFR), depending on disease stage and patient-related factors [
3]. During the course of CRC, mutations accumulate in genes controlling cell survival and proliferation.
Several of the genes afflicted in CRC belong to the RAS pathway [
4]. The RAS pathway involves at least 4 key protein families (RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular regulated kinase (ERK)) that are activated in a consecutive manner, creating a signaling cascade that eventually results in gene regulation. Approximately 50 % of metastatic CRCs have activating mutations in the
KRAS or
NRAS genes [
5‐
7]. Patients with
RAS mutations do not respond favorably to treatment with neutralizing anti-EGFR antibodies [
8]. BRAF is the best characterized of three closely related RAF proteins [
9]. The
BRAF gene harbors an activating mutation (V600E) in 5–12 % of all CRC [
10]. Tumors may have mutations either in
KRAS or
BRAF though, as a rule, not in both [
11]. Activation of certain protein kinase C (PKC) isoforms, such as PKCɛ, by phospholipase Cγ1 (PLCγ1), promotes RAF activation [
12]. BRAF in turn activates the dual tyrosine and serine/threonine kinase MEK, which is mutated only very rarely in CRC [
13]. The serine/threonine kinases ERK1/2, downstream of MEK, are also not mutated in CRC [
13].
Cell proliferation is regulated also by the cytoplasmic tyrosine kinase c-SRC, which is activated when phosphorylated on tyrosine residue (Y) 418 in the kinase domain and which is inhibited when phosphorylated on the C-terminal Y527 [
14]. c-SRC expression is reported to be 5–8 fold higher in premalignant colorectal polyps than in normal mucosa and a correlation between elevated c-SRC levels and CRC progression/metastatic potential has been suggested [
15‐
17]. c-SRC kinase inhibitors are being developed for therapeutic purposes [
18,
19]. Resistance to BRAF inhibition in melanoma can be overcome by inhibiting c-SRC activity [
20], indicating a convergence of the pathways.
Cell survival is regulated by the phosphoinositide 3-kinase (PI3K)/AKT pathway which, via mammalian target of rapamycin complex 1 (mTORC1), eventually results in activation of p70S6 kinase and gene induction [
21]. The serine/threonine kinase AKT is activated by phosphorylation of threonine (T) 308 located in the kinase domain and serine (S) 473 in the C-terminal end, by phosphatidylinositol-dependent kinase 1 (PDK1) and mTORC2, respectively. The PI3K/AKT pathway is negatively regulated by the lipid phosphatase, phosphatase and tensin homolog (PTEN) [
22], which has been identified as a tumor suppressor [
23]. About 15 % of all CRCs have activating or suppressing mutations in the
PI3KCA gene, encoding the p110α catalytic subunit of PI3K, as well as the
PTEN gene [
24]. Moreover, in wild type (non-mutated)
KRAS gene tumors, the presence of PI3K and PTEN mutations indicates a poor prognosis [
25].
To identify mutations in cancer is part of an effort to individualize each patient’s treatment. However, mutations may not result in changes in protein expression levels and/or activity, and the mutation status of a particular cancer may fail to convey information about additional events occurring during progression of the disease, which may override a particular mutation, e.g. compensatory upregulation of other proteins and pathways [
26]. There is no doubt that the EGFR/RAS pathway and downstream ERK1/ERK2 activities are essential in CRC etiology and disease progression [
27]. However, predicting RAS pathway activity is particularly complex as there are several different upstream and parallel activators on different levels and many alternative feedback loops [
26]. Apart from the regulation of RAS activity through GTPase regulatory proteins (GAPs and GEFs), downstream signaling in the RAS pathway can be induced or modulated through activities in several other pathways, including the PLCγ/PKC, PI3K/AKT and c-SRC pathways. Another complicating aspect of RAS signaling in CRC is chromosomal fragility. 85 % of sporadic CRC cases display chromosomal instability, chromosome amplification and translocation leading to aneuploidy (see [
28] and refs therein), whereas the remaining 15 % of patients have high-frequency microsatellite instability phenotypes i.e. frameshift mutations and base pair substitutions [
29]. The chromosomal instability of CRC clearly influences the biological consequence of the mutations. Thus, taken together, the presence of a mutation in a signaling protein does not necessarily predict activity in the corresponding signaling pathway.
Due to the existing challenges in CRC therapy, the development of rapid and sensitive screens to measure the biological activity of key signal transducers, which could serve as drug targets or as predictive or prognostic biomarkers, is warranted. Previously, the CRC proteome has been investigated using mass spectrometry to identify up- and downregulation of proteins, using mostly cell lines but also, to some extent, patient samples [
30]. However, this is the first study to comprehensively address the proliferative signaling proteome in CRC tissues. For this purpose, we have developed protocols for highly sensitive, robotized isoelectric focusing, to show that signaling in the RAS pathway is dysregulated in human CRC primary tumors compared with normal mucosa. Moreover, by computational and geometric assessment of the signal transduction patterns in the different tissues examined (normal, stage II and stage IV CRC), we show that combinations of patterns from several pathways could serve as biomarkers and be exploited for the classification of tissues as normal or cancerous. We suggest that further refinement of complex signatures can be exploited for prognostic purposes.
Methods
Tumor biopsy collection
The colorectal tumor sampling and characterization of the anonymous samples was approved by the Uppsala Regional Ethical Review Board (no 2007/005 and 2000/001). Prior to the operation the patient was asked by the responsible surgeon to donate tumor tissue and blood samples for future molecular studies. Patients agreeing to participate were given written study information and signed an informed consent form. When the surgical specimen (colon) was removed from the patient, it was immediately transported on ice to the histopathological department and a clinical pathologist cut a 5x5x5 mm biopsy from the periphery of the primary tumor and a 10x10 mm normal mucosa more than 5 cm from the primary tumor. The biopsies were immediately placed, without addition of medium, in test tubes, which were stored at -80 °C until analyses were made. Thirty-three colon cancer samples were selected from a set of frozen tumor biopsies collected from patients operated upon for colorectal cancer at the hospitals in Karlstad or Västerås, Sweden. Seventeen of the 33 patients had stage II colon cancer and 16 had stage IV colon cancer. Samples of normal mucosa from 18 patients were available for analyses.
Cell culture and VEGF treatment
Human umbilical vein endothelial cells (HUVECs; ATCC; Manassas, VA) were cultured on gelatin-coated 10 cm tissue culture petri dishes in endothelial cell basal medium MV2 (EBM-2, C-22221; PromoCell, Heidelberg, Germany) with supplemental pack C-39221, containing 5 % FCS, epidermal growth factor (5 ng/ml), VEGF (0.5 ng/ml), basic FGF (10 ng/ml), Insulin-like Growth Factor (Long R3 IGF, 20 ng/ml), hydrocortisone (0.2 μg/ml), and ascorbic acid (1 μg/ml). HUVECs at passages 3–6 were used. For experimental purposes, ECs were serum-starved overnight and plated in EBM-2 medium, 1 % FCS without growth factor supplement and treated with/without VEGF (50 ng/ml, Preprotech, Rocky Hill, NJ) for 7.5 min or 15 min. The cells were lysed in a commercial RIPA buffer containing protease inhibitor mix (# 040-482, ProteinSimple, Santa Clara, CA) and phosphatase inhibitors (# 040-510, ProteinSimple). The lysates were clarified by centrifugation and protein concentrations were determined by using BCA Protein Assay Kit (Pierce ThermoFisher Scientific, Rockford, IL, USA).
Isoelectric focusing
CRC tissue samples were lysed in RIPA buffer containing phosphatase and protease inhibitors (ProteinSimple). The tissue lysates were clarified by centrifugation and protein concentration was measured by using BCA Protein Assay Kit (Pierce/ThermoFisher Scientific). Samples were run in triplicates. Lysates were mixed with ampholyte premix (# 040-972, G2 pH 5-8 or # 040-968, G2 pH 3-10) and fluorescent isoelectoric point (pI) standards (# 040-646, pI Standard Ladder 3) before being loaded into the NanoPro 1000 system (ProteinSimple) for analysis. Isoelectric focusing was performed in capillaries filled with a mixture of cell lysate (0.05–0.2 mg/ml protein), fluorescently labeled pI standards, and ampholytes. The separated proteins were cross-linked onto the capillary wall using UV light, and immobilization was followed by immunoprobing with anti-ERK1/2 (1:50, # 9102), anti-pERK1/2 (# 4377, 1:50) and anti-PLCγ1 (# 2822, 1:50) antibodies from Cell Signaling Technology (Danvers, MA); anti-AKT (# sc-8312, 1:20), p70S6 kinase (# sc-8418, 1:50), and MEK 1/2 (# sc-436, 1:50) antibodies from Santa Cruz Biotechnology Inc. (Dallas, Texas); anti c-SRC (# ab47405, 1:50) antibodies from Abcam; and anti-EGFR (# 05-484, 1:50) antibodies from Merck Millipore (Darmstadt, Germany). Analysis of HSP 70 (# NB600-571, 1:500), Novus Biologicals (Littleton, CO) was run in parallel for normalization. HRP-conjugated secondary antibodies were used, either from ProteinSimple (Goat anti rabbit-HRP IgG, # 041-081 and Goat anti mouse-HRP IgG, # 040-655 both at 1:100) or from Jackson ImmunoResearch (West Grove, PA) (Donkey anti-Rabbit IgG, # 711-035-152 and Donkey anti-Mouse-HRP IgG # 711-035-150, both at 1:300), to detect the signal. In some cases, signal amplification steps were employed by using an amplified rabbit (# 041-126, 1:100) or amplified mouse (# 041-127, 1:100) secondary antibody detection kit (ProteinSimple). The signal was visualized by enhanced chemiluminescence (ECL) and captured by a charge-coupled device (CCD) camera. The digital image was analyzed and peak area quantified with Compass software (ProteinSimple). The peak area of the protein of interest was normalized to the area of heat shock protein 70 (HSP70) in the sample, analyzed in parallel.
Lambda phosphatase digestion
Some samples were enzymatically dephosphorylated by incubating 8–15 μg of cell lysate with 50 units of lambda phosphatase (# 14-405; Upstate Biotechnology, Charlottesville, VA), for 5-30 min at 30 °C, where incubation time was titrated independently for each signaling component. Digested samples were subjected to immunoblotting or isoelectric focusing as described above.
Mutation analysis
KRAS pyro-sequencing mutational analysis was performed according to the manufacturer’s protocol for the PyroMark™ Q24 KRAS Pyro kit (QIAGEN GmbH, Hilden, Germany) and the use of PCR primers previously described for
KRAS codon 12/13 [
31], codon 61 [
32], and for
BRAF codon 600 [
31]. Ten ng genomic DNA from the patients tumor tissue was used for each PCR reaction. Twenty μl PCR product was then subjected to Pyro-sequencing analysis using Streptavidin Sepharose High Performance beads (GE Healthcare, Chicago IL), PyroMark Gold Q96 reagents, PyroMark Q24 2.0.6 software, and a Q24 instrument (QIAGEN). Sequencing primer for
KRAS codon 12/13 was 5′-AACTTGTGGTAGTTGGAGCT-3′, for codon 61 5′-TCTTGGATATTCTCGACACAGCAG-3′, and for
BRAF codon 600 5′-TGATTTTGGTCTAGCTACA-3′. Due to sub-optimal DNA quality, two samples were not suitable for mutation analysis (denoted “unclear” in the figures).
Immunoblotting
Ten μg of CRC tissue- or cell lysate was mixed with lithium dodecylsulfate sample buffer and Sample Reducing Agent and heated at 70 °C for 10 min. The proteins were resolved on NuPAGE Novex 4–12 % Bis-Tris SDS PAGE Gel (Life Technologies, Carldsbad, CA) and transferred onto PVDF membranes (Immobilon-P IPVH00010; Merck Millipore). The membranes were blocked by using 5 % (w/v) nonfat dry milk/BSA in TBS with 0.1 % Tween 20 for 1 h at RT, which was followed by incubation over night at 4 °C with primary antibodies pERK 1/2 (# 4377, 1:1000), ERK1/2 (# 9102, 1:1000), SRC pY416 (# 2101, 1:1000), SRC pY527 (# 2105, 1:1000), pAKT (# 4060, 1:1000), AKT (# 9272, 1:1000), PLCγ1 (# 2822, 1:1000), all from Cell Signaling Technology. SRC (# ab47405, 1:1000) and β2M (# ab75853, 1:2000) were from Abcam. EGFR (# 05-484, 1:2000) and GAPDH (# MAB374, 1:1500) from Merck Millipore, α-Tubulin (# T9026, 1:1000) from Sigma-Aldrich (Saint Louis, MI), p70S6 kinase (# sc-8418, 1:2000) from Santa Cruz Biotechnologies Inc, HSP 70 (# NB600-571, 1:1000) from Novus Biologicals. Proteins of interest were detected with HRP-conjugated donkey anti-rabbit IgG antibody (# NA934, 1: 15000) or sheep anti-mouse IgG antibody (# NA931, 1: 15000), visualized with using ECL Prime (# RPN2232) and exposed to either the Hyperfilm ECL (# 28906837) all from GE Healthcare. Signals were visualized using the ChemiDoc™ MP Imaging System (Bio-Rad Laboratories, Herkules, CA) according to the provided protocol.
Statistical analysis
The Mann-Whitney U test was used to calculate two-tailed p-values of the null hypothesis that the populations of the two compared features (proteins) are the same. p < 0.05 was considered statistically significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001. The Mann-Whitney test is a conservative, non-parametric test that was chosen to preclude false detections arising from assumptions of data distribution.
Identification of tissue signatures
For assessment of data sets and the creation and evaluation of convex hulls for classification of the tissue samples based on signatures, see Additional file
1: Figure S3, Characteristics of the data set and errors.
Discussion
Substantial research efforts over the last decades have resulted in increased understanding of CRC mutations and molecular consequences; still, due to the complexity of the tumor biology and the heterogeneity of the cancer, CRC remains a fatal disease. Here, we show that signaling pathways regulating cell survival and proliferation were differently regulated in CRC tissues compared to normal mucosa. Expression of ERK1 and SRC appeared significantly suppressed in CRC tissues compared with normal mucosa while expression of AKT and PLCγ1 were upregulated. See Table
1 for a summary of the pattern of proliferative CRC signaling identified in this study.
Table 1
Summary of changes in signaling components between normal and CRC tissues
EGFR | + | + | + | Similar levels in benign, CRC II and IV. |
pAKT/AKT | + | + | + | Total levels of pAKT and AKT upregulated in CRC but pAKT/AKT ratios were similar in the different samples. |
p70S6K | + | + | + | Similar levels in benign, CRC II and IV. |
PLCγ1 | - | +++ | + + | Low or no PLCγ1 expression in benign samples and higher levels in CRC. pPLCγ1 was not detected in any samples. |
SRC pY527/SRC | +++ | + | + | Low or no SRC pY418 in all samples. Lower SRC pY527/SRC ratios in CRC II and IV compared to benign. |
pERK1/ERK1 | +++ | + | + | Reduced pERK1/ERK1 ratio in CRC II and IV compared to benign. |
pERK2/ERK2 | ++ | ++ | ++ | Similar ratios benign, CRC II and IV. |
MEK1/2 | + | + | + | Similar levels in benign, CRC II and IV. |
Signaling was analyzed using capillary isoelectric focusing, which we found to be superior to conventional immunoblotting in sensitivity and resolution. After loading of samples and antibodies, the processing was robotized, resulting in highly reproducible and sensitive detection. For example, ERK1/2 protein was detected in 2.5 ng of CRC lysate per capillary (corresponding to 6.25 μg/ml total lysate). Moreover, protein variants, phosphorylated at different residues, could be separated and quantified independently. For ERK1/2 proteins, six of the isoforms (pERK1, ppERK1, ERK1, pERK2, ppERK2, ERK2) could be identified and quantified in relation to the house keeping proteins analyzed in parallel. In comparison, conventional immunoblotting run on the same samples required much more protein for each analysis. It often failed to resolve protein phospho-variants and reproducibility was low, in part due to problems with transfer of proteins to the filter. Ongoing efforts include adapting the isoelectric focusing protocol for the detection of signal transducers in formalin-fixed, paraffin-embedded samples to make the procedure applicable in clinical routines.
Using the isoelectric focusing strategy, several important observations were made that can be related to earlier reports on CRC signaling (see also summary in Table
1):
I)
AKT: In agreement with our findings on increased AKT protein expression in the CRC tissues, colorectal adenomas and carcinomas frequently overexpress AKT [
39] at an early stage in the disease. Moreover, other components in the PI3K/AKT pathway are affected in CRC. The most common event is a loss of expression of, or mutation in PTEN, which occurs in close to 50 % of the premalignant lesions [
40].
II)
PLCγ1: Studies on a limited number of CRC samples showed increased PLCγ1 protein levels whereas other PLC family members, PLCβ1 and PLCδ1, remained unaffected [
41]. However, whether the increased protein levels are accompanied by increased phospholipase activity in CRC remains unclear. Phosphorylation of PLCγ1 is known to induce its catalytic activity however, we failed to detect phosphorylated PLCγ1 in the CRC samples studied here.
III)
c-SRC is a key signal transducer whose activity may initiate most, if not all, other pathways related to cell proliferation [
42], and the expression and activity of c-SRC have been associated with CRC progression [
15,
16,
42]. However, in several studies, c-SRC activity has been analyzed using an in vitro immune complex kinase assay on cell lines, rather than on clinical samples [
43‐
45]. The lack of pY418 phosphorylated c-SRC and the decrease in expression in disease shown here (Fig.
4), indicate that c-SRC does not drive CRC tumor cell proliferation. Also, pathways potentially induced as a consequence of c-SRC activation in CRC, such as the Scatter factor/c-Met pathway, may not be crucial [
46]. c-SRC kinase activity is regulated by tyrosine phosphorylation/dephosphorylation. We detected c-SRC pY527 in all samples, although the amount decreased in disease. As there was no parallel increase in c-SRC pY418, it appears that overall, there is limited c-SRC activity in CRC. The decrease in pY527 levels may depend on phosphatase activity with c-SRC being dephosphorylated
e.g. by the tyrosine phosphatase PTPRO [
47]. Apart from the well characterized positive regulatory pY418 and negative regulatory pY527, there are other phosphorylation sites in c-SRC including pS17 and pY215 whose functions have remained unclear [
36]. The many phospho-SRC peaks identified in the isoelectric focusing indicate that, in CRC, c-SRC can become modified at yet additional sites. However, as the critical pY418 is lacking, it is questionable whether c-SRC is a suitable target for CRC therapy. Another complicating aspect of studying c-SRC’s role in cancer biology is the high degree of structural relatedness with other SRC family tyrosine kinases (SFKs), first and foremost the ubiquitously expressed FYN and YES. Thus, we cannot exclude that c-SRC, YES, and FYN phosphoproteins may all have been detected by the c-SRC reagents used here, due to the highly conserved phosphorylation sites in all three members. Overall, insight on the role of the different SFKs in CRC is lacking.
IV)
ERK1/2: Aberrant colon crypt foci, which are believed to predict a malignant process, were analyzed using a similar methodology to that applied in this study, revealing elevated levels of both pERK1 and pERK2 irrespective of KRAS and BRAF mutation status [
48]. ERK1 and ERK2 are highly related structurally and are largely co-regulated and indeed, in many aspects, redundant. However, ERK2, but not ERK1, has been shown to contribute to RAS-induced oncogenic signaling [
49], and yet, ERK1 has been implicated in the negative regulation of ERK2 [
50]. Therefore, the reduced pERK1 levels in CRC that we describe here may unleash ERK2 activity, resulting in increased oncogenic signaling in primary tumors. Regulation of ERK1/2 signaling is truly complex, with scaffold proteins, including KSR1/2, IQGAP1, MP1, and β-Arrestin1/2, participating in the regulation of the ERK1/2 MAP kinase cascade [
26]. Furthermore, ERK1/2 are dephosphorylated by several different phosphatases [
51] that may be differently expressed.
Several decades of ambitious basic and clinical research have demonstrated the challenges in identifying reliable biomarkers in cancer. Challenges include the complexity of the primary tumor tissue consisting of, apart from the tumor cells, a range of host-derived endothelial, fibroblast and inflammatory cells; potential differences between the primary tumor and metastasis; and the possibility that biopsies may not be representative. In this study, the proportion of tumor cells ranged from about 30–60 % in most samples, based on the estimation of mutated DNA/total DNA in the samples (data not shown). An important conclusion from the current study is that the combination of several features from the conducted analyses allows a very high confidence in classifying the tissues as normal or cancerous. The particular combination of pERK1, SRC peak 6, and p70S6K peak 3 selected here to distinguish cancer tissue from normal tissue, may or may not indicate convergence of the included pathways in CRC signaling. The main objective of the selection was to allow unbiased diagnosis. Thus, we propose that reliable prognostic and diagnostic biomarkers should be designed using complex patterns rather than a single molecular or genetic marker. For clinical translation, the isoelectric focusing analyses can easily be made routine and scaled up. For example, 96 unique samples could be run in parallel to yield information on three or more selected pathways (by mixing several appropriate antibodies yielding non-overlapping patterns) in a 10 h run in a robotized set-up. Combined with the powerful computational evaluation to identify sets of signaling components showing significant characteristics, this strategy could prove to be clinically feasible for diagnostic purposes beyond the treatment of CRC. Based on the results obtained this far, we predict that the measurement of seven protein forms (i.e. selected peaks from the electropherograms) would be sufficient for the correct classification of both non-cancerous versus cancerous tissue as well as for the CRC grade. Moreover, analysis of a larger cohort of samples, combined with information on chosen therapy and disease outcomes, would allow the use of supervised learning for identification of clinically relevant subtypes.
Acknowledgements
The authors gratefully acknowledge Ross Smith, Uppsala University, for linguistic revision and Marcus Thuresson, Statisticon AB, for revision of statistical analyses.
NP is a vascular/cancer biologist with a PhD from the Jawaharlal Nehru University, New Delhi, India, and currently a senior postdoc with Prof. Lena Claesson-Welsh.
TEMN is a Systems Biologist with a PhD in Automatic Control from KTH Royal Institute of Technology, Stockholm, Sweden; currently an Assistant Professor at the National Cheng Kung University, Tainan, Taiwan.
MS is a cancer and molecular biology researcher with a PhD from Uppsala University, Sweden, and currently a development manager at the molecular pathology unit at Uppsala University Hospital.
PÅ is an MD and expert in colorectal surgery, with a PhD in neuroscience from Karolinska Institute, Sweden.
HB is an MD, PhD, working as a colorectal surgeon and associate professor at the Department of surgical sciences, Uppsala University Hospital, Sweden.
PN is an MD and expert in clinical oncology with a PhD from Uppsala University, Sweden, and a professor in Oncology at this university.
SN is a cancer systems biologist with a PhD from Gothenburg University, Sweden; he is currently an associate professor and group leader at Uppsala University, Sweden.
LCW is a vascular/cancer biologist with expertise in signal transduction. She is a professor in Medical Biochemistry at Uppsala University.